Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:50:23 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ARDX - ARDELYX INC - https://ardelyx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ARDX - Q0.27.06·8.002.57.32+0.324.63,181.022,34913,3467.15  7.34  6.998.40  3.2119:57:45Feb 0515 min RT 2¢

Recent Trades - Last 10 of 13346
Time ETExPriceChangeVolume
19:57:45Q7.390.395
19:57:45Q7.38990.38995
19:52:44Q7.38920.3892400
19:50:55Q7.380.3835
19:40:59Q7.340.34686
19:40:59Q7.34010.3401686
19:36:32Q7.37630.376330
18:45:42Q7.390.391,000
18:30:35Q7.34120.34121
18:30:35Q7.350.351

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 08:00U:ARDXNews ReleaseArdelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
2026-02-03 08:29U:ARDXNews ReleaseArdelyx Receives New Patent for Tenapanor
2026-01-28 08:29U:ARDXNews ReleaseFirst Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
2026-01-23 12:56U:ARDXNews ReleaseBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
2026-01-08 08:30U:ARDXNews ReleaseArdelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
2025-11-07 16:05U:ARDXNews ReleaseReal-World Evidence Studies of XPHOZAH(TM) (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
2025-11-05 08:00U:ARDXNews ReleaseArdelyx to Participate at the Jefferies Global Healthcare Conference in London
2025-11-04 08:00U:ARDXNews ReleaseArdelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
2025-10-30 16:01U:ARDXNews ReleaseArdelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-28 08:01U:ARDXNews ReleaseArdelyx Presents Data that Continues to Support the Benefits of IBSRELA(TM) (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting
2025-10-21 08:00U:ARDXNews ReleaseArdelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week
2025-10-13 08:35U:ARDXNews ReleaseArdelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
2025-10-13 08:30U:ARDXNews ReleaseArdelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
2025-08-25 08:00U:ARDXNews ReleaseArdelyx to Participate in Upcoming Investor Conferences
2025-08-04 16:08U:ARDXNews ReleaseArdelyx Announces Changes to the Executive Leadership Team
2025-08-04 16:02U:ARDXNews ReleaseArdelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-21 08:00U:ARDXNews ReleaseArdelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
2025-06-02 16:05U:ARDXNews ReleaseArdelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
2025-05-21 08:00U:ARDXNews ReleaseArdelyx to Participate at the Jefferies Global Healthcare Conference 2025
2025-05-06 08:02U:ARDXNews ReleaseArdelyx Presents Data Supporting IBSRELA(TM) (tenapanor) at Digestive Disease Week 2025 Conference